Cellosaurus logo
expasy logo

Cellosaurus XMMME-001 (CVCL_F817)

[Text version]
Cell line name XMMME-001
Synonyms IND1
Accession CVCL_F817
Resource Identification Initiative To cite this cell line use: XMMME-001 (RRID:CVCL_F817)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8759.
Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce XomaZyme-Mel (XMMME-001-RTA) which was evaluated in several clinical trials for metastatic melanoma patients (DOI=10.3390/antib1010039).
Monoclonal antibody isotype: IgG2a.
Monoclonal antibody target: Human melanoma tumor specific HMW antigen.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_3411 (P3X63Ag8)
Category Hybridoma
Publications

PubMed=6609971; DOI=10.4049/jimmunol.133.1.137
Nancy A. Kernan, Robert W. Knowles, Michael J. Burns, Hal E. Broxmeyer, Li Lu, Howard M. Lee, Russell T. Kawahata, Patrick J. Scannon, Bo Dupont;
Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
J. Immunol. 133:137-146(1984)

Patent=US4590071
Patrick J. Scannon, Lynn E. Spitler, Howard M. Lee, Russell T. Kawahata, Ronald P. Mischak;
Human melanoma specific immunotoxins.
Patent number US4590071, 20-May-1986

DOI=10.3390/antib1010039
Nurit Becker, Itai Benhar;
Antibody-based immunotoxins for the treatment of cancer.
Antibodies (Basel) 1:39-69(2012)

Cross-references
Cell line collections (Providers) ATCC; HB-8759
Cell line databases/resources CLO; CLO_0009652
Encyclopedic resources Wikidata; Q54994849
Entry history
Entry creation11-Feb-2013
Last entry update21-Mar-2023
Version number6